MONTREAL, QUEBEC -- (MARKET WIRE) -- January 04, 2007 -- Ecopia BioSciences Inc. (TSX: EIA) (“Ecopia”) and Caprion Pharmaceuticals Inc. (“Caprion”) have announced earlier today that they have entered into a combination agreement whereby they have agreed, subject to certain conditions, to combine their respective businesses through a plan of arrangement pursuant to which Ecopia and Caprion will amalgamate to form a new company with a strategic objective to create a leading oncology and infectious disease company. The amalgamated company will have a portfolio of three active clinical therapeutic programs in advanced stages of development in cancer and infectious disease on a rapid path to commercialization and a sustainable pipeline of new opportunities.
